The Food and Drug Administration is investigating what caused a batch of the active ingredient for Johnson & Johnson’s COVID-19 vaccine to be scrapped for failing to meet quality standards at a contract manufacturing plant, according to a person familiar with the matter.

The FDA may send an inspection team to assess the situation at the Baltimore plant operated by contractor Emergent BioSolutions Inc. EBS, -13.40%,  the person said.

Leave a Reply

Your email address will not be published. Required fields are marked *